A Study to Assess the Effectiveness and Side Effects of GSK2798745 in Participants With Chronic Cough

PHASE1/PHASE2TerminatedINTERVENTIONAL
Enrollment

17

Participants

Timeline

Start Date

April 5, 2018

Primary Completion Date

October 8, 2018

Study Completion Date

October 8, 2018

Conditions
Cough
Interventions
DRUG

GSK2798745

GSK2798745 tablets will be available as white to almost white, round, film-coated tablets (micronized active pharmaceutical ingredient \[API\]) to be taken with a glass of water (approximately 240 mL).

DRUG

Placebo

Placebo tablets will be available as white to almost white, round, film-coated tablets to be taken with a glass of water (approximately 240 mL).

Trial Locations (8)

M23 9LT

GSK Investigational Site, Manchester

M23 9L

GSK Investigational Site, Manchester

BT9 7BL

GSK Investigational Site, Belfast

BT9 7B

GSK Investigational Site, Belfast

HU16 5JQ

GSK Investigational Site, Cottingham

HU16 5

GSK Investigational Site, Cottingham

NE29 8NH

GSK Investigational Site, North Shields

NE29 8

GSK Investigational Site, North Shields

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

Biomedical Advanced Research and Development Authority

FED

lead

GlaxoSmithKline

INDUSTRY

NCT03372603 - A Study to Assess the Effectiveness and Side Effects of GSK2798745 in Participants With Chronic Cough | Biotech Hunter | Biotech Hunter